Risk factors for Mycobacterium abscessus infection in cystic fibrosis patients; a case-control study

Journal of Cystic Fibrosis

Volumn 11, Issue 4, 2012, Pages 340-343

  Verregghen, Maarten ^a   Heijerman, Harry G ^b   Reijers, Monique ^c   van Ingen, Jakko ^c   van der Ent, Cornelis K ^d  

^a UTRECHT UNIVERSITY   (Netherlands)

^b HAGA HOSPITAL   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Aspergillus fumigatus; Cystic fibrosis; Mycobacterium abscessus; Risk factors; Stenotrophomonas maltophilia

Indexed keywords

AMIKACIN; AZITHROMYCIN; CEFOXITIN; COLISTIN; IMIPENEM; MACROLIDE; STEROID; TIGECYCLINE; TOBRAMYCIN;

ADULT; ANTIMICROBIAL THERAPY; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; BACTERIUM ISOLATE; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; CYSTIC FIBROSIS; DIABETES MELLITUS; DISEASE PREDISPOSITION; ENVIRONMENTAL EXPOSURE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; LUNG INJURY; MAINTENANCE THERAPY; MALE; MYCOBACTERIOSIS; MYCOBACTERIUM ABSCESSUS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RISK FACTOR; STENOTROPHOMONAS MALTOPHILIA; SYMPTOM;

ADOLESCENT; ADULT; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CASE-CONTROL STUDIES; CHILD; CYSTIC FIBROSIS; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MALE; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; NONTUBERCULOUS MYCOBACTERIA; RISK FACTORS; STENOTROPHOMONAS MALTOPHILIA; YOUNG ADULT;

EID: 84862487597     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2012.01.006     Document Type: Article

References (18)

1. Ratjen F., Döring G. Cystic fibrosis. Lancet Feb 22 2003, 361(9358):681-689.
2. Harrison F. Microbial ecology of the cystic fibrosis lung. Microbiology 2007, 153:917-923.
3. Griffith D.E. Emergence of nontuberculous mycobacteria as pathogens in cystic fibrosis. Am J Respir Crit Care Med 2003, 167:810-812.
4. Griffith D.E., Aksamit T., Brown-Elliott B.A., et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007, 175:367-416.
5. van Ingen J., Boeree M.J., Dekhuijzen P.N., van Soolingen D. Environmental sources of rapid growing nontuberculous mycobacteria causing disease in humans. Clin Microbiol Infect 2009, 15:888-893.
6. Jönsson B.E., Gilljam M., Lindblad A., Ridell M., Wold A.E., Welinder-Olsson C. Molecular epidemiology of Mycobacterium abscessus, with focus on cystic fibrosis. J Clin Microbiol 2007, 45:1497-1504.
7. Roux A.L., Catherinot E., Ripoll F., et al. Multicenter study of prevalence of nontuberculous mycobacteria in patients with cystic fibrosis in France. J Clin Microbiol 2009, 47:4124-4128.
8. Olivier K.N., Weber D.J., Wallace R.J., et al. Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 2003, 167:828-834.
9. van Ingen J., de Zwaan R., Dekhuijzen R.P., Boeree M.J., van Soolingen D. Clinical relevance of Mycobacterium chelonae-abscessus group isolation in 95 patients. J Infect 2009, 59:324-331.
10. Esther C.R., Esserman D.A., Gilligan P., Kerr A., Noone P.G. Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. J Cyst Fibros 2010, 9:117-123.
11. Spicuzza L., Sciuto C., Vitaliti G., Di Dio G., Leonardi S., La Rosa M. Emerging pathogens in cystic fibrosis: ten years of follow-up in a cohort of patients. Eur J Clin Microbiol Infect Dis 2009, 28:191-195.
12. Pihet M., Carrere J., Cimon B., Chabasse D., Delhaes L., Symoens F., et al. Occurrence and relevance of filamentous fungi in respiratory secretions of patients with cystic fibrosis-a review. Med Mycol Jun 2009, 47(4):387-397.
13. Ebert D.L., Olivier K.N. Nontuberculous mycobacteria in cystic fibrosis. Infect Dis Clin North Am 2002, 16:221-233.
14. Sexton P., Harrison A.C. Susceptibility to nontuberculous mycobacterial lung disease. Eur Respir J 2008, 31:1322-1333.
15. Mussaffi H., Rivlin J., Shalit I., Ephros M., Blau H. Nontuberculous mycobacteria in cystic fibrosis associated with allergic bronchopulmonary aspergillosis and steroid therapy. Eur Respir J 2005, 25:324-328.
16. Nash K.A., Brown-Elliott B.A., Wallace R.J. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother 2009, 53:1367-1376.
17. Renna M., Schaffner C., Brown K., et al. Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J Clin Invest 2011, 121:3554-3563.
18. Jarand J., Levin A., Zhang L., Huitt G., Mitchell J.D., Daley C.L. Clinical and microbiological outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis 2011, 52:565-571.